Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up
Ester Badia Aranda; Cristina Fernández Marcos; Aida Puebla Maestu; Visitación Gozalo Marín; Raquel Vinuesa Campo; Sara Calvo Simal; Judith Gómez Camarero;
Gastroenterol Hepatol. 2022;45:767-79
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Joan Martínez-Campreciós; Mar Riveiro-Barciela; Raquel Muñoz-Gómez; María-Carlota Londoño; Mercé Roget; Miguel Ángel Serra; Desamparados Escudero-García; Laura Purchades; Manuel Rodríguez; Juan E. Losa-García; María L. Gutiérrez; Isabel Carmona; Javier García-Samaniego; Luís Morano; Ignacio Martín-Granizo; Marta Montero-Alonso; Martín Prieto; Manuel Delgado; Natalia Ramos; María A. Azancot; Francisco Rodríguez-Frías; Maria Buti;
Gastroenterol Hepatol. 2023;46:594-602
Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review
Luis Gutiérrez-Rojas; Jesús José de la Gándara Martín; Luisa García Buey; Juan I. Uriz Otano; Álvaro Mena; Carlos Roncero;
Gastroenterol Hepatol. 2023;46:382-96